BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12829134)

  • 1. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
    Anscher MS; Marks LB; Shafman TD; Clough R; Huang H; Tisch A; Munley M; Herndon JE; Garst J; Crawford J; Jirtle RL
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):988-95. PubMed ID: 12829134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.
    Anscher MS; Marks LB; Shafman TD; Clough R; Huang H; Tisch A; Munley M; Herndon JE; Garst J; Crawford J; Jirtle RL
    J Clin Oncol; 2001 Sep; 19(17):3758-65. PubMed ID: 11533099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
    De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
    Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
    Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan.
    Zhao L; Wang L; Ji W; Wang X; Zhu X; Hayman JA; Kalemkerian GP; Yang W; Brenner D; Lawrence TS; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1385-90. PubMed ID: 19231104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Levels of IL-8 and TGF-β1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study.
    Wang S; Campbell J; Stenmark MH; Zhao J; Stanton P; Matuszak MM; Ten Haken RK; Kong FS
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):615-621. PubMed ID: 28581403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
    Onimaru R; Shirato H; Shimizu S; Kitamura K; Xu B; Fukumoto S; Chang TC; Fujita K; Oita M; Miyasaka K; Nishimura M; Dosaka-Akita H
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):126-35. PubMed ID: 12694831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
    Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L
    J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta1 in serum and induced sputum for predicting radiation pneumonitis in patients with non-small cell lung cancer after radiotherapy.
    Wang J; Qiao XY; Lu FH; Zhou ZG; Song YZ; Huo JJ; Liu X
    Chin J Cancer; 2010 Mar; 29(3):325-9. PubMed ID: 20193119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.
    Hayman JA; Martel MK; Ten Haken RK; Normolle DP; Todd RF; Littles JF; Sullivan MA; Possert PW; Turrisi AT; Lichter AS
    J Clin Oncol; 2001 Jan; 19(1):127-36. PubMed ID: 11134205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
    Kepka L; Tyc-Szczepaniak D; Bujko K
    J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
    J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
    Zhao L; Sheldon K; Chen M; Yin MS; Hayman JA; Kalemkerian GP; Arenberg D; Lyons SE; Curtis JL; Davis M; Cease KB; Brenner D; Anscher MS; Lawrence TS; Kong FM
    Lung Cancer; 2008 Feb; 59(2):232-9. PubMed ID: 17905467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.